GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Recbio Technology Co Ltd (HKSE:02179) » Definitions » Debt-to-Equity

Jiangsu Recbio Technology Co (HKSE:02179) Debt-to-Equity : 0.61 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Jiangsu Recbio Technology Co Debt-to-Equity?

Jiangsu Recbio Technology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$66.76 Mil. Jiangsu Recbio Technology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$645.06 Mil. Jiangsu Recbio Technology Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$1,171.91 Mil. Jiangsu Recbio Technology Co's debt to equity for the quarter that ended in Dec. 2023 was 0.61.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Jiangsu Recbio Technology Co's Debt-to-Equity or its related term are showing as below:

HKSE:02179' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03   Med: 0.05   Max: 0.61
Current: 0.61

During the past 5 years, the highest Debt-to-Equity Ratio of Jiangsu Recbio Technology Co was 0.61. The lowest was -0.03. And the median was 0.05.

HKSE:02179's Debt-to-Equity is ranked worse than
77.89% of 1063 companies
in the Biotechnology industry
Industry Median: 0.15 vs HKSE:02179: 0.61

Jiangsu Recbio Technology Co Debt-to-Equity Historical Data

The historical data trend for Jiangsu Recbio Technology Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Recbio Technology Co Debt-to-Equity Chart

Jiangsu Recbio Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
-0.02 -0.03 0.05 0.17 0.61

Jiangsu Recbio Technology Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Equity Get a 7-Day Free Trial 0.05 0.07 0.17 0.41 0.61

Competitive Comparison of Jiangsu Recbio Technology Co's Debt-to-Equity

For the Biotechnology subindustry, Jiangsu Recbio Technology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jiangsu Recbio Technology Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jiangsu Recbio Technology Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Jiangsu Recbio Technology Co's Debt-to-Equity falls into.


Jiangsu Recbio Technology Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Jiangsu Recbio Technology Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(66.762 + 645.064) / 1171.914
=0.61

Jiangsu Recbio Technology Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(66.762 + 645.064) / 1171.914
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Recbio Technology Co  (HKSE:02179) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Jiangsu Recbio Technology Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Jiangsu Recbio Technology Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Jiangsu Recbio Technology Co (HKSE:02179) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Recbio Technology Co Ltd (HKSE:02179) » Definitions » Debt-to-Equity
Comparable Companies
HKSE:01477 HKSE:02487 HKSE:02171 HKSE:01521 HKSE:02257 HKSE:02157 HKSE:00775 HKSE:02480 HKSE:02696 HKSE:06855 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No. 888 Yaocheng Avenue, Medical High-tech District, Jiangsu Province, Taizhou, CHN
Website
https://www.recbio.cn
Jiangsu Recbio Technology Co Ltd is an vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. Company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
Executives
Feng Tao 2201 Interest of corporation controlled by you
Bei Jing Jun Lian Cheng Yuan Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Zhu Linan 2201 Interest of corporation controlled by you
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Jun Qi Jia Rui Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Jun Cheng He Zhong Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Jun Lian Jie You Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Hui Zhi Yi Hao Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Chen Hao 2201 Interest of corporation controlled by you
La Sa Jun Qi Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Chao Rui Yi Yao Ke Ji He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Lyfe Capital Fund Iii (dragon), L.p.
Liu Yong
Chen Wei 2201 Interest of corporation controlled by you
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you

Jiangsu Recbio Technology Co (HKSE:02179) Headlines

No Headlines